Avidity Biosciences has been granted a patent for polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD). The patent includes a claim for a polynucleic acid molecule conjugate targeting the DUX4 gene for RNA interference. GlobalData’s report on Avidity Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Avidity Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Avidity Biosciences's grant share as of April 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Polynucleic acid conjugate for treating fshd through rna interference
A recently granted patent (Publication Number: US11912779B2) discloses a polynucleic acid molecule conjugate designed to target the DUX4 gene. The conjugate consists of an anti-transferrin receptor antibody or its antigen binding fragment linked to a polynucleic acid molecule with specific nucleic acid sequences and modifications. The polynucleic acid molecule is engineered to mediate RNA interference against the DUX4 gene, offering a potential therapeutic approach for conditions associated with DUX4 expression.
The patent details various aspects of the polynucleic acid molecule conjugate, including the length of the molecule, specific nucleic acid sequences, modifications such as 2'-F modified nucleotides, and the presence of sense and antisense strands. Additionally, the patent describes the composition of the anti-transferrin receptor antibody or its fragments, which can be non-human, human, humanized, chimeric, monoclonal, or other forms. The conjugate also includes a linker connecting the antibody to the polynucleic acid molecule, with options for different types of linkers and ratios between the components. Overall, the patent provides a detailed framework for a novel therapeutic approach targeting the DUX4 gene, potentially opening up new possibilities for treating related disorders.
To know more about GlobalData’s detailed insights on Avidity Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
